AI in Recruitment: What It Can and Cannot Replace in High-Stakes Life Sciences Hiring
The Life Sciences sector—encompassing pharmaceuticals, biotechnology, and medical device manufacturing—operates on a razor-thin margin for error. In this industry, a “bad hire” isn’t just a budgetary line item; it can derail a clinical trial, compromise regulatory compliance, or delay a life-saving therapy from reaching the market. As Artificial Intelligence (AI) permeates the human resources landscape, […]
DNA First: Why Organisational Values Should Drive Every Hiring Decision
In the high-stakes race for top talent, companies often fall into the “competency trap.” We scour resumes for prestigious degrees, technical certifications, and years of experience in specific niches. We prioritize what a candidate can do over who they are. However, as many leaders eventually discover—often the hard way—a brilliant software engineer who doesn’t collaborate, or a high-performing sales executive […]
Why Most First Launches Fail
A first commercial launch is one of the most unforgiving transitions in life sciences. The company moves from proving a molecule’s promise to proving an enterprise can deliver—reliably, compliantly, and at scale. Most first launches do not “fail” because the product is weak. They fail because leadership underestimates the integrated complexity of commercialization: manufacturing and […]
Why Quality & CMC Are Now CEO-Critical Functions
For years, many life sciences leaders treated Quality and CMC (Chemistry, Manufacturing, and Controls) as necessary enablers: essential for compliance, but fundamentally operational. That framing no longer reflects reality. Today, Quality and CMC are board-level risk and value drivers. They determine how quickly you can progress from clinical promise to commercial reliability, how resilient your […]
The Hidden Manufacturing Talent Crisis
The Hidden Manufacturing Talent Crisis In life sciences, manufacturing has quietly become one of the most consequential constraints on growth. Not because companies lack capital, assets, or demand—but because they lack people with the right operational “scar tissue” to scale complex products under GMP conditions. This is the hidden manufacturing talent crisis: the sector’s manufacturing […]
What VC-Backed Biotech Boards Expect from Leadership
In VC-backed biotech, boards are not simply governance bodies—they are active stakeholders underwriting scientific risk with time-bound capital. Their expectations of leadership are therefore different from those in large pharma and meaningfully more demanding than many first-time CEOs anticipate. Boards are betting on a company’s ability to convert uncertainty into value through credible plans, disciplined […]
Why Rare Disease Requires a Different Commercial Strategy
Commercial playbooks built for primary care or broad specialty indications routinely underperform in rare disease. Not because the fundamentals of commercialization change—but because the market mechanics do. Rare disease is defined by small, dispersed patient populations, diagnostic complexity, and high clinical and financial stakes. Success depends less on reach and repetition and more on precision: […]